Sorbent hemoperfusion in end-stage renal disease: An in-depth review

Advances in Renal Replacement Therapy

Volumn 9, Issue 1, 2002, Pages 19-25

  Winchester, James F ^a,b   Ronco, Claudio ^a,b  

^a SUNY DOWNSTATE MEDICAL CENTER   (United States)

^b UNIVERSITY OF PADOVA   (Italy)

Author keywords

Hemodialysis; Mesopores; Middle molecular weight toxius; Sorbents; Uremia

Indexed keywords

ACTIVATED CARBON; CELLULOSE ACETATE; DIVINYLBENZENE; HEPARIN; POLYSTYRENE; SORBENT;

DEVICE; HEMODIALYSIS; HEMOPERFUSION; HUMAN; HYDROGEL; KIDNEY DISEASE; LAMINAR FLOW; MICROENCAPSULATION; PARTICLE SIZE; POROSITY; PRIORITY JOURNAL; REVIEW; RISK BENEFIT ANALYSIS; UREMIA;

EID: 0036205510     PISSN: 10734449     EISSN: None     Source Type: Journal    
DOI: 10.1053/jarr.2002.30472     Document Type: Review

References (47)

1. Characterization of flow-dynamic pattern in a new sorbent cartridge for combined hemoperfusion-hemodialysis
2. A convenient haemoperfusion micro-apparatus over charcoal for the treatment of endogenous and exogenous intoxications. Its use as an artificial kidney
3. Clinical experience with the Yatzidis charcoal artificial kidney
4. Semipermeable aqueous microcapsules (artificial cells): With emphasis on experiments in an extracorporeal shunt system
5. Middle molecule adsorption from ultrafiltrate for use in intensive care medicine
6. First clinical experience with an adjunctive hemoperfusion device designed specifically to remove β2-microglobulin in hemodialysis
7. Introduction to sorbents
8. Activated carbon: Properties, selection, and evaluation
9. Adsorption characteristics of cellulose acetate coated charcoals
10. Solute, amino acid, and hormone changes with coated charcoal hemoperfusion in uremia
11. Influence of haemoperfusion on plasma levels of hormones and β-methyldigoxin
12. Behavior of trace metals during hemoperfusion
13. Polymeric adsorbent for removing toxic proteins from blood of patients with kidney failure
14. New adsorption column (lixelle) to eliminate β-2 microglobulin for direct hemoperfusion
15. Effects of a new adsorbent column for removing beta-2-microglobulin from circulating blood of dialysis patients
16. The use of adsorbents in the removal of cytokines
17. A novel immunoadsorption device for removing beta2-microglobulin from whole blood
18. Microcapsule artificial kidney in replacement of renal function. With emphasis on adsorbent hemoperfusion
19. Complement and leukocyte-mediated pulmonary dysfunction in hemodialysis
20. Loss of fibronectin in plasma of patients with shock and septicaemia and after haemoperfusion in patients with severe poisoning
21. Sorbent membrane dialysis in uremia
22. Evaluation of efficiency of carbon fibrous haemosorbents
23. Hemoperfusion in chronic uremia
24. Resin artificial kidney
25. Clinical evaluation of chronic intermittent and short-term hemoperfusion in patients with chronic renal failure using semipermeable microcapsules (artificial cells) formed from membrane coated activated charcoal
26. Characterization of possible toxic metabolites in uremia and hepatic coma based on the clearance spectrum for larger molecules by the ACAC microcapsule artificial kidney
27. Serum middle molecule levels in uremia during long-term intermittent hemoperfusion with ACAD (coated charcoal) microcapsule artificial kidney
28. Removal of uremic small and middle molecules and free amino acids by carbon hemoperfusion
29. Assessment of clinical trials of charcoal hemoperfusion in uremic patients
30. Hemoperfusion in uremia: Effect of time, solute competition and biocompatibility on column adsorption
31. Hemoperfusion results in uremia
32. Comparative studies on the effect of hemoperfusion and hemodialysis on the elimination of some uremic toxins
33. Evaluation of a new coated charcoal for hemoperfusion in uremia
34. Hemodialysis and hemoperfusion in the treatment of uremic pericarditis. A study of 13 cases
35. Clinical and fundamental studies of cellulose coated bead-shaped charcoal haemoperfusion in chronic renal failure
36. Effect of haemoperfusion on the left ventricular systolic function in patients with chronic uraemia
37. Treatment of uraemic peripheral neuritis by direct haemoperfusion with activated charcoal
38. Clinical results of direct charcoal hemoperfusion for endogenous and exogenous intoxication
39. Long-term reduced time hemoperfusion-hemodialysis compared to standard dialysis. A preliminary crossover analysis
40. Long-term evaluation of charcoal haemoperfusion combined with dialysis for uraemic patients
41. Clinical experience of bead-shaped charcoal hemoperfusion in chronic renal failure and fulminant hepatic failure
42. Shortened treatment time by combined hemodialysis and hemoperfusion
43. Adequacy of hemoperfusion for blood purification in uremia
44. The removal of uremic toxins
45. Rationale for combined hemoperfusion/hemodialysis in uremia, in dialysis, dialyzers and sorbents. Where are we going?
46. Reduction in circulating β2-microglobulin level for the treatment of dialysis-related amyyloidosis